Global Medical REIT (NYSE:XRN) CEO Mark Okey Decker Jr Acquires 6,875 Shares of Stock

Key Points

• CEO Mark Okey Decker Jr. purchased 6,875 shares of Global Medical REIT at an average of $35.92, investing approximately $246,950 and increasing his ownership to 75,199 shares.
• Global Medical REIT reported quarterly EPS of $4.78, beating the $0.83 consensus estimate by $3.95, on revenue of $39.75 million.
• Analyst sentiment remains mixed, with an overall “Hold” rating and a consensus price target of $40.25 versus the stock’s recent price of $36.52; institutional investors own 57.52% of shares.

Global Medical REIT Inc. (NYSE:XRN - Get Free Report) CEO Mark Okey Decker, Jr. acquired 6,875 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were purchased at an average cost of $35.92 per share, for a total transaction of $246,950.00. Following the acquisition, the chief executive officer owned 75,199 shares in the company, valued at $2,701,148.08. This represents a 10.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Global Medical REIT Price Performance

XRN stock traded up $0.25 during midday trading on Thursday, reaching $36.52. 100,235 shares of the stock were exchanged, compared to its average volume of 89,274. Global Medical REIT Inc. has a 52 week low of $29.05 and a 52 week high of $39.93. The company has a fifty day moving average price of $36.59 and a 200 day moving average price of $35.80. The company has a debt-to-equity ratio of 1.68, a current ratio of 0.68 and a quick ratio of 0.68. The stock has a market capitalization of $483.50 million, a PE ratio of 9.82 and a beta of 1.09.

Global Medical REIT (NYSE:XRN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $4.78 EPS for the quarter, beating analysts' consensus estimates of $0.83 by $3.95. Global Medical REIT had a return on equity of 13.74% and a net margin of 36.82%.The firm had revenue of $39.75 million for the quarter. As a group, analysts expect that Global Medical REIT Inc. will post 3.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. raised its stake in shares of Global Medical REIT by 30.5% in the second quarter. Invesco Ltd. now owns 1,518,668 shares of the company's stock worth $10,524,000 after purchasing an additional 355,355 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Global Medical REIT by 8.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,514,954 shares of the company's stock worth $10,499,000 after acquiring an additional 119,538 shares in the last quarter. Man Group plc raised its holdings in shares of Global Medical REIT by 1.7% in the second quarter. Man Group plc now owns 600,943 shares of the company's stock valued at $4,165,000 after purchasing an additional 10,192 shares during the last quarter. Heartland Advisors Inc. grew its position in Global Medical REIT by 177.4% in the 4th quarter. Heartland Advisors Inc. now owns 423,460 shares of the company's stock worth $14,288,000 after purchasing an additional 270,786 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Global Medical REIT by 13.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 388,605 shares of the company's stock valued at $3,400,000 after buying an additional 45,243 shares during the last quarter. 57.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

XRN has been the subject of a number of recent analyst reports. Compass Point reissued a "neutral" rating and set a $38.00 target price (down from $50.00) on shares of Global Medical REIT in a research report on Thursday, May 7th. Zacks Research raised shares of Global Medical REIT to a "hold" rating in a research note on Wednesday, July 22nd. Raymond James Financial began coverage on shares of Global Medical REIT in a research report on Wednesday, June 17th. They set a "market perform" rating for the company. BMO Capital Markets lifted their target price on shares of Global Medical REIT from $39.00 to $40.00 and gave the stock a "market perform" rating in a research note on Monday, July 13th. Finally, Weiss Ratings lowered shares of Global Medical REIT from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Global Medical REIT has an average rating of "Hold" and a consensus target price of $40.25.

Key Headlines Impacting Global Medical REIT

Here are the key news stories impacting Global Medical REIT this week:

• Positive Sentiment: Director Charles Fitzgerald purchased 14,000 shares for approximately $500,920 at an average price of $35.78, increasing his direct ownership by 11.21%. This followed his purchase of another 27,600 shares, worth about $991,944, on August 10. SEC insider purchase filing
• Positive Sentiment: CEO Mark Okey Decker Jr. bought 8,000 shares for $287,040 on August 10 and an additional 550 shares for $19,800 on August 11. The purchases increased his holdings by 13.38% and 0.81%, respectively, signaling management confidence in the company’s valuation and outlook. CEO insider buying report
• Positive Sentiment: Global Medical REIT reported quarterly earnings per share of $4.78, exceeding the $0.83 consensus estimate by $3.95, with revenue of $39.75 million. The company posted a 36.82% net margin and 13.74% return on equity, while analysts expect full-year EPS of $3.06.
• Positive Sentiment: Some analysts remain constructive: Citizens JMP raised its price target to $42 from $40 and maintained an outperform rating. The average analyst price target is $40.25, above the recent trading level.
• Neutral Sentiment: Institutional ownership remains substantial at 57.52%. Invesco increased its position, and several other investment firms recently initiated or expanded holdings, providing some support from professional investors.
• Negative Sentiment: Analyst sentiment is mixed, with an overall “Hold” rating. Compass Point cut its price target to $38 from $50, Wall Street Zen downgraded the stock to “Sell,” and Raymond James initiated coverage at “Market Perform.”
• Negative Sentiment: The REIT carries meaningful leverage, with a debt-to-equity ratio of 1.68 and current and quick ratios of 0.68, factors that could limit financial flexibility if interest rates or property-market conditions worsen.

Global Medical REIT Company Profile

Global Medical REIT NYSE: GMRE is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.

Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source